Summary: SimBioSys’s TumorSight Viz provides AI-driven 3D visualization and clinical decision support to assist breast surgeons in treatment planning for early-stage breast cancer, aligning with National Comprehensive Cancer Network guidelines for patient-centered decisions.

Key Takeaways

  • TumorSight Viz has received FDA clearance and is now available to assist breast surgeons in early-stage breast cancer treatment planning with AI-driven segmentation and clinical decision support (CDS) tools.
  • The platform supports 3D MRI visualization and direct PACS integration, aligning with National Comprehensive Cancer Network guidelines for breast-conserving surgeries.
  • TumorSight Viz’s CDS functionality provides data-driven insights, aiding surgeons in making individualized, evidence-based treatment decisions.

———————————————————————————————————————————————————————————

SimBioSys has received U.S. FDA clearance for the updated TumorSight Viz, now available for use by breast surgeons in the U.S. This version includes AI-driven tumor segmentation, streamlined MRI access through PACS connectivity, and a clinical decision support (CDS) feature that provides evidence-based treatment options. The CDS tool is designed to assist breast surgeons in treatment planning for early-stage breast cancer patients.

With the FDA’s recent mandate for breast density reporting, MRI use as a supplementary screening tool is expected to increase. TumorSight Viz enables 3D visualization of MRI data, aligning with NCCN guidelines for breast-conserving surgeries. “

TumorSight Viz’s clinical decision support is a groundbreaking resource for breast surgeons and oncologists, helping them select the best options for each patient and fostering shared decision-making,” says Freya Schnabel, MD, director of breast surgery at NYU Langone Health’s Perlmutter Cancer Center.

TumorSight Viz Enhancements

  • AI-Driven Segmentation: Provides accurate 3D visualization to support treatment planning.
  • Clinical Decision Support (CDS): Supplies data-driven insights for surgical planning.
  • Direct MRI Access via PACS Systems: Integrates MRI access, streamlining the clinical workflow.

National Comprehensive Cancer Network guidelines encourage individualized treatment planning, including options for breast reconstruction and oncoplastic surgery. TumorSight Viz supports these guidelines, aiding surgeons in achieving functional and cosmetic outcomes.

Advancements in Breast Cancer Care

SimBioSys’s TumorSight platform combines AI visualizations and CDS tools to support treatment decisions for breast cancer patients. “This second FDA clearance marks a significant milestone in precision medicine for cancer,” says Barry Rosen, MD, chief medical officer at SimBioSys. “TumorSight Viz’s latest capabilities bring us closer to an era of precision surgery that supports breast conservation when desired.”

TumorSight Viz is intended for MRI visualization and analysis for early-stage or locally advanced breast cancer patients.